Provention leaps on deal with Sanofi to co-promote teplizumab

7 October 2022

Even before the diabetes candidate gets regulatory approval, US biotech Provention Bio (Nasdaq: PRVB) revealed it has entered into a co-promotion agreement with French pharma major Sanofi (Euronext: SAN) for the launch of Provention's lead investigational drug candidate teplizumab. Provention’s shares were up almost than 26% at $6.22 by close of trading on Thursday.

The agreement enables Provention Bio to leverage Sanofi's expertise, capabilities and commercial resources to support the potential launch of teplizumab, which is currently under review by the US Food and Drug Administration (FDA), for the delay of clinical type 1 diabetes in at-risk individuals.

The regulator, which delayed making a decision on the drug in July, has set a user fee goal date of November 17, 2022 for the Biologics License Application (BLA). Assuming it gains approval, peak sales of $1.17 billion have been forecast for teplizumab.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK